{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000023","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.482311+00:00","generated_at":"2026-06-15T09:07:37.462224+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen Q1 net loss $11.3M; cash $183.8M; Phase 1 ACU193 topline due Q3 2023","bullets":["Net loss of $11.3M for Q1 2023 vs $9.1M in Q1 2022; no revenue reported.","Cash, equivalents and marketable securities $183.8M as of March 31, 2023, down from $193.4M at Dec 31, 2022.","R&D expenses $8.7M (up from $6.0M) driven by ongoing Phase 1 INTERCEPT-AD trial of ACU193.","Company expects to report topline Phase 1 data for ACU193 in early Alzheimer's in Q3 2023, with FDA interaction in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000023","json":"https://secwatch.observer/filing/0001576885-23-000023.json","markdown":"https://secwatch.observer/filing/0001576885-23-000023.md","text":"https://secwatch.observer/filing/0001576885-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000023/0001576885-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000023/abos-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:07:37.462224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6227a22fb6d41e22162f1e6a1a12e956b3cb6d3","claim":"Acumen Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income $11.3 million.","evidence_excerpt":"Net loss was $11.3 million for the three-month period ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000023/0001576885-23-000023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"$11.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}